| [1] |
中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组，全国幽门螺杆菌研究协作组，刘文忠，等.第五次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志，2017，56（7）：532-545.
|
| [2] |
Malfertheiner P，Megraud F，O′Morain CA，et al.Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report[J].Gut，2017，66（1）：6-30.
|
| [3] |
Sapmaz F，Kalkan IH，Atasoy P，et al.A non-inferiority study：modified dual therapy consisting higher does of rabeprazole is as successful as standard quadruple therapy in eradication of helicobacter pylori[J].Am J Ther，2017，24（4）：e393-e398.
|
| [4] |
索宝军，田雪丽，李彩玲，等.雷贝拉唑和阿莫西林双联2 周方案在幽门螺杆菌感染初治患者中的疗效观察[J].中华医学杂志，2019，99（48）：3781-3785.
|
| [5] |
Tai WC，Liang CM，Kuo CM，et al.A 14 day esomeprazoleand amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan：a prospective randomized trial[J].J Antimicrob Chemother，2019，74（6）：1718-1724.
|
| [6] |
黄继平，黄艳娟，袁小刚，等.深圳龙岗地区幽门螺杆菌耐药状况分析及耐药对治疗的影响[J].实用医学杂志，2015，31（14）：2382-2384.
|
| [7] |
Zhang YX，Zhou LY，Song ZQ，et al.Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing：a prospective serial study[J].World J Gastroenterol，2015，21（9）：2786-2792.
|
| [10] |
吕涛，倪丽，吴娟，等.深圳幽门螺杆菌根除率变化和耐药分析多中心研究[J].中华消化杂志，2020，40（8）：557-561.
|
| [11] |
陈丽萍，金雷.大剂量艾司奥美拉唑镁对幽门螺杆菌相关性胃炎的治疗效果分析[J].中国医学前沿杂志（电子版），2019，11（1）：83-86.
|
| [8] |
Zhou L，Zhang J，Song Z，et al.Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment：A Randomized Trial[J].Helicobacter，2016，21（2）：91-99.
|
| [9] |
Hong J，Shu X，Liu D，et al.Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection：an open -label，randomized，single-centre clinical trial[J].J Antimicrob Chemother，2016，71（8）：2280-2285.
|
| [12] |
Yang X，Wang JX，Han SX，et al.High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment：A systematic review and meta-analysis[J].Medicine（Baltimore），2019，98（7）：e14396.
|
| [13] |
Yu L，Luo L，Long X，et al.High-dose PPI-amoxicillin dual therapy with or without bismuth for firstline Helicobacter pylori therapy：A randomized trial[J].Helicobacter，2019，24（4）：e12596.
|
| [14] |
Song ZQ，Zhou LY，Xue Y，et al.A comparative study of 14-day dual therapy （esomeprazole and amoxicillin four times daily）and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication：A randomized trial[J].Helicobacter，2020，25（6）：e12762.
|
| [15] |
Yang J，Zhang Y，Fan L，et al.Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori[J].Am J Gastroenterol，2019，114（3）：437-445.
|
| [16] |
Suzuki S，Gotoda T，Kusano C，et al.Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment：a multicentre randomised trial in Japan[J].Gut，2020，69（6）：1019-1026.
|
| [17] |
Gotoda T，Kusano C，Suzuki S，et al.Clinical impact of vonoprazan-based dual therapy with amoxicillin for H.pylori infection in a treatment-naive cohort of junior high school students in Japan[J].J Gastroenterol，2020，55（10）：969-976.
|
| [18] |
Furuta T，Yamade M，Kagami T，et al.Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan，amoxicillin and clarithromycin for eradication of helicobacter pylori[J].Digestion，2020，101（6）：743-751.
|
